[Estrogen substitution in the postmenopause--effect and compliance].
At least one of four women will suffer from osteoporosis with fractures of vertebrae, forearm or hip. Maintenance of bone mass is a crucial argument for long-term estrogen replacement for prophylaxis of osteoporosis. 2 mg estradiol or 0.625 mg conjugated estrogens orally or 50 to 100 micrograms estradiol percutaneously are equally sufficient for prevention of osteoporosis. The additional use of a progestogen in women with intact uterus may support the antiresorptive effects of estrogens. Improvement of patients' compliance-administered today by only 25% of postmenopausal women in Germany through sufficient information upon estrogen replacement therapy provided by the medical community is a rewarding task for physicians and scientists engaged in the field of menopause and prevention of osteoporosis.
Dören
M
M
Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde, Westfälischen Wilhelms-Universität, Münster.
D015914:Estrogen Replacement Therapy; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010349:Patient Compliance; D017698:Postmenopause / Q000187:drug effects*; D011372:Progestins / Q000008:administration & dosage
D011372:Progestins
Ostrogensubstitution in der Postmenopause--Wirkung und Compliance.